Translating Next-Generation Science Into Transformative Gene TherapiesLearn About Our Programs

Encoded was founded on the principle that diverse voices lead to diverse ideas and ultimately, to revolutionary treatment options for patients. Our diversity – whether gender, ethnicity, sexual …

Programs Encoded is building an internally developed pipeline of best- and potentially first-in-class therapies focused on neurological disorders.

Encoded Therapeutics Strengthens Clinical Leadership Team with Appointment of Professor Joseph Sullivan, M.D., as Vice President of Clinical Development December 05, 2025 Encoded Therapeutics …

Encoded carefully designs clinical studies to assess safety and efficacy of its investigational gene therapies for the treatment of neurological disorders. People considering enrolling their child in an …

Ever wondered what it takes to make a gene therapy? Join us on a virtual lab tour at Encoded’s headquarters in South San Francisco. Meet a few of our talented scientists ready to explain what …

Encoded will be providing additional updates on its research pipeline, which is focused on both rare genetic and common disease programs, in addition to clinical progress with ETX101 for Dravet …

Contact Directory Patients Community and Clinical Trials [email protected] Healthcare Providers [email protected] Media [email protected] Finance/Accounting …

“The support we have received from this visionary group of investors will allow us to develop into a fully-integrated therapeutics company and establish Encoded as a leading innovator in gene therapy.”

Encoded is developing ETX101, a potential one-time, disease-modifying gene regulation therapy for SCN1A+ Dravet syndrome. ETX101, Encoded’s lead program, is specifically designed to address the …